Drug manufacturer Sun Pharmaceutical Industries has made announcement about the launching of the generic Amifostine for injection 500mg, which is therapeutically equivalent to MedImmunne’s Ethyol.

Sun Pharma’s product is being sold in the US market through its marketing partner Caraco Pharmaceutical Laboratories. In US, Ethyol has yearly sales of around USD 80 million.

The company has got USFDA nod for marketing the generic Ethyol, used for cancer treatment, on March 17.

Sun Pharma, being the first-to-file an ANDA for generic Ethyol® with a para IV certification, had a 180-day marketing exclusivity.

Ethyol® is covered under 3 patents - ‘471 (July 31, 2012), ‘731 (July 31, 2012) and ‘409 (Dec 8, 2017).

This ANDA was registered against all the patents.

In the meantime, Medimmune has filed a case in the District Court of Maryland and the case is under litigation.

At 1:29pm, the shares of the company lost 3.4% at Rs 1,208 on the Bombay Stock Exchange (BSE).